EORTC-55092-GCG

Back to Clinical Trials Database

Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma.

Study documentation

Trial Status	Closed to Patient Entry
Dates	Date of activation: 20-Jul-2012 Date Step1 close: 16-May-2018
Data management at EORTC	Yes
Design	Phase 1-2 Randomized open label
Targeted Sample size	EORTC Groups: 88 - All Groups: 88
Treatment	Drug Bevacizumab, Carboplatin, Paclitaxel, Pazopanib
Study Staff	Corneel Coens (Statistician) , EORTC Headquarters, Brussels Sara Meloen (Pharmacovigilance Manager) , EORTC Headquarters, Brussels Ellen Peeters (Senior Clinical Operations Manager) , EORTC Headquarters, Brussels Jelle Stans (Regulatory Affairs Manager) , EORTC Headquarters, Brussels
Type of cancer	Ovarian Fallopian Tube
Participating groups	EORTC Gynecological Cancer Group
Recruiting centers	C.H.U. Sart-Tilman (Liege, Belgium) Centre Hospitalier Regional De La Citadelle (Liege, Belgium) Erasmus MC Hospital (Rotterdam, Netherlands) Hospital Universitario 12 De Octubre (Madrid, Spain) Hospital Universitario San Carlos (Madrid, Spain) ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) (Badalona - (Barcelona), Spain) Institut Jules Bordet (Anderlecht, Belgium) Radboud University Medical Center Nijmegen (Nijmegen, Netherlands)
Protocol summary	http://clinicaltrials.gov/study/NCT01402271
NCT number	NCT01402271
EudraCT	2010-024077-39
Financial Support	Educational Grant